Oncogenic osteomalacia

Endocrinologist

Volumn 15, Issue 2, 2005, Pages 65-68

  Menon, V Usha ^a   Nair, V ^a   Kumar, H ^a   Rajanikanth, U ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Body pain and stiffness; Fibroblast growth factor 23; Hemangiopericytoma; Hypophosphatemia; Oncogenic osteomalacia

Indexed keywords

CALCIUM; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PERTECHNETIC ACID TC 99M; PHOSPHATE; PROSTATE SPECIFIC ANTIGEN;

ACETABULUM; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAMNESIS; ARTICLE; BLOOD POOL SCINTISCANNING; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMUR NECK; FOLLOW UP; HEMANGIOPERICYTOMA; HUMAN; HYPOPHOSPHATEMIA; MALE; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PUBIS SYMPHYSIS; RIB; SACROILIAC JOINT; URINE PH; VERTEBRA;

EID: 15244349285     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000157816.48111.cb     Document Type: Article

References (18)

1. Cai Q, Hodgson SF, Kao PC, et al. Inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994;330:1645-1649.
2. Nuovo MA, Dorfman HD, Sun CC, et al. Tumour induced osteomalacia and rickets. Am J Surg Pathol. 1989;13:588-599.
3. Reese DM, Rosen PJ. Oncogenic osteomalacia associated with prostatic cancer. J Urol. 1997;158:887.
4. Fukumoto S, Takeyuchi Y, Nagano A, et al. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone. 1999;25:375-377.
5. Avila NA, Skarulis M, Rubino DM, et al. Oncogenic osteomalacia. Lesion detection by MR skeletal survey. AJR Am J Roentgenol. 1996;167:343-345.
6. Rhee Y, Lee JD, Shin KH, et al. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf). 2001;54:551-554.
7. Garcia CA, Spencer R. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med. 2002;27:582-583.
8. Fukumoto S, Yamashita T. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens. 2002;11:385-389.
9. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87:4957-4960.
10. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500-6505.
11. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314:409-414.
12. Saito H. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1 alpha, 25-dihydroxyvitamin D3 production. J Biol Chem. 2003;278:2206-2211.
13. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435.
14. Jonsson KB. Extracts from tumors causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cells. J Endocrinol. 2001;169:613-620.
15. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656-1663.
16. Larsson T. Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur J Endocrinol. 2003;148:269-276.
17. Nelson AE, Bligh RC, Mirams M, et al. Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003;88:4088-4094.
18. Mathew JT, Seshadri MS, Thomas K, et al. Osteomalacia - fifty five patients seen in a teaching institution over a 4 year period. J Assoc Physicians India. 1994;42:692-694.